Compare Stocks: XBIT, IMRX, SABS, and QTTB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMRX Immuneering	$3.73 -2.1%	$4.41	$3.38 ▼ $8.48	$246.50M	0.46	714,369 shs	726,263 shs
QTTB Q32 Bio	$8.65 -1.7%	$11.07	$1.90 ▼ $23.57	$261.97M	0.31	1.11 million shs	404,045 shs
SABS SAB Biotherapeutics	$2.84 -6.6%	$3.32	$2.44 ▼ $5.15	$276.60M	0.58	785,462 shs	1.02 million shs
XBIT XBiotech	$1.93 -2.0%	$2.19	$1.86 ▼ $3.44	$60.06M	0.79	62,057 shs	121,735 shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMRX Immuneering	-2.10%	+3.90%	-14.84%	-13.66%	-30.28%
QTTB Q32 Bio	-1.70%	+15.03%	-9.52%	-42.90%	+226.42%
SABS SAB Biotherapeutics	-6.58%	+12.25%	-16.22%	-19.09%	-5.33%
XBIT XBiotech	-2.03%	-8.96%	-11.47%	-14.98%	-22.49%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMRX Immuneering	$3.73 -2.1%	$4.41	$3.38 ▼ $8.48	$246.50M	0.46	714,369 shs	726,263 shs
QTTB Q32 Bio	$8.65 -1.7%	$11.07	$1.90 ▼ $23.57	$261.97M	0.31	1.11 million shs	404,045 shs
SABS SAB Biotherapeutics	$2.84 -6.6%	$3.32	$2.44 ▼ $5.15	$276.60M	0.58	785,462 shs	1.02 million shs
XBIT XBiotech	$1.93 -2.0%	$2.19	$1.86 ▼ $3.44	$60.06M	0.79	62,057 shs	121,735 shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMRX Immuneering	-2.10%	+3.90%	-14.84%	-13.66%	-30.28%
QTTB Q32 Bio	-1.70%	+15.03%	-9.52%	-42.90%	+226.42%
SABS SAB Biotherapeutics	-6.58%	+12.25%	-16.22%	-19.09%	-5.33%
XBIT XBiotech	-2.03%	-8.96%	-11.47%	-14.98%	-22.49%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMRX Immuneering	3.00	Buy	$15.71	321.29% Upside
QTTB Q32 Bio	2.89	Moderate Buy	$32.17	271.87% Upside
SABS SAB Biotherapeutics	2.73	Moderate Buy	$12.00	322.54% Upside
XBIT XBiotech	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest XBIT, IMRX, SABS, and QTTB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/16/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/12/2026	QTTB Q32 Bio	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$40.00
10/1/2026	QTTB Q32 Bio	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
9/28/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/28/2026	QTTB Q32 Bio	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$29.00
9/28/2026	QTTB Q32 Bio	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$29.00
9/21/2026	IMRX Immuneering	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/17/2026	SABS SAB Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/16/2026	QTTB Q32 Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
9/14/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/7/2026	QTTB Q32 Bio	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy

(Data available from 10/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMRX Immuneering	N/A	N/A	N/A	N/A	$3.38 per share	N/A
QTTB Q32 Bio	$53.74M	4.79	$1.49 per share	5.80	$3.41 per share	2.54
SABS SAB Biotherapeutics	$1.32M	195.77	$0.32 per share	8.90	$3.18 per share	0.89
XBIT XBiotech	N/A	N/A	N/A	N/A	$4.60 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMRX Immuneering	-$56.03M	-$1.04	N/A	N/A	N/A	N/A	-27.15%	-25.75%	11/11/2026 (Estimated)
QTTB Q32 Bio	$29.82M	$3.00	4.25	N/A	N/A	N/A	50.17%	29.49%	11/12/2026 (Estimated)
SABS SAB Biotherapeutics	$13.27M	-$1.30	N/A	N/A	N/A	N/A	-6.74%	-6.06%	11/13/2026 (Estimated)
XBIT XBiotech	-$45.54M	-$1.48	N/A	N/A	N/A	N/A	-31.62%	-30.29%	N/A

Latest XBIT, IMRX, SABS, and QTTB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	Q3 2026	SABS SAB Biotherapeutics	-$0.27	N/A	N/A	N/A	$0.13 million	N/A
11/12/2026	Q3 2026	QTTB Q32 Bio	-$0.36	N/A	N/A	N/A	N/A	N/A
11/11/2026	Q3 2026	IMRX Immuneering	-$0.29	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	XBIT XBiotech	$0.03	-$0.22	-$0.25	-$0.22	$7.00 million	N/A
8/6/2026	Q2 2026	SABS SAB Biotherapeutics	-$0.2830	-$0.28	+$0.0030	-$0.28	$0.13 million	N/A
8/5/2026	Q2 2026	IMRX Immuneering	-$0.2643	-$0.27	-$0.0057	-$0.27	N/A	N/A
8/5/2026	Q2 2026	QTTB Q32 Bio	-$0.46	-$0.44	+$0.02	-$0.44	$0.75 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMRX Immuneering	N/A	N/A	N/A	N/A	N/A
QTTB Q32 Bio	N/A	N/A	N/A	N/A	N/A
SABS SAB Biotherapeutics	N/A	N/A	N/A	N/A	N/A
XBIT XBiotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMRX Immuneering	N/A	19.47	19.47
QTTB Q32 Bio	N/A	20.30	20.30
SABS SAB Biotherapeutics	0.01	9.22	9.22
XBIT XBiotech	N/A	33.15	33.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMRX Immuneering	67.65%
QTTB Q32 Bio	31.32%
SABS SAB Biotherapeutics	7.82%
XBIT XBiotech	55.70%

Insider Ownership

Company	Insider Ownership
IMRX Immuneering	14.90%
QTTB Q32 Bio	34.46%
SABS SAB Biotherapeutics	7.39%
XBIT XBiotech	21.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMRX Immuneering	57	64.70 million	55.06 million	Optionable
QTTB Q32 Bio	22	29.77 million	19.51 million	Optionable
SABS SAB Biotherapeutics	86	90.99 million	84.26 million	Optionable
XBIT XBiotech	87	30.49 million	24.06 million	Optionable

XBIT, IMRX, SABS, and QTTB Headlines

Recent News About These Companies

XBiotech Inc.: XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers

October 23 at 3:14 PM | finanznachrichten.de

XBiotech names co-CEOs as Simard joins Shivaswamy in leadership

October 23 at 3:14 PM | streetinsider.com

XBiotech Appoints Jan-Paul Simard as Co-Chief Executive Officer Alongside Dr. Sushma Shivaswamy

October 23 at 9:30 AM | quiverquant.comQ

XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers

October 23 at 9:17 AM | globenewswire.com

XBiotech Inc.: XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer

October 19, 2026 | finanznachrichten.de $https://www.finanznachrichten.de/nachrichten-2026-10/69873296-xbiotech-inc-xbiotech-announces-positive-phase-ii-final-efficacy-results-from-investigator-sponsored-taskin-trial-in-refractory-metastatic-colorecta-399.htm$

XBiotech's TASKIN Trial Meets Primary Efficacy Criterion In Metastatic Colorectal Cancer

October 19, 2026 | rttnews.com

XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer

October 19, 2026 | finance.yahoo.com

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

June 15, 2026 | globenewswire.com

XBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ Radar

May 14, 2026 | tipranks.com

XBiotech: Q4 Earnings Snapshot

March 13, 2026 | chron.com

XBiotech’s New Trial: A Potential Game-Changer for Rheumatoid Arthritis Treatment?

October 28, 2025 | msn.com

XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insiders

August 28, 2025 | finance.yahoo.com

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

March 2, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

March 1, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 28, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 27, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 26, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 25, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 24, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 23, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT, IMRX, SABS, and QTTB Company Descriptions

Immuneering NASDAQ:IMRX

$3.73 -0.08 (-2.10%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$3.71 -0.02 (-0.64%)

As of 10/23/2026 08:00 PM Eastern

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Q32 Bio NASDAQ:QTTB

$8.65 -0.15 (-1.70%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$8.36 -0.30 (-3.41%)

As of 10/23/2026 07:30 PM Eastern

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

SAB Biotherapeutics NASDAQ:SABS

$2.84 -0.20 (-6.58%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$2.84 0.00 (-0.18%)

As of 10/23/2026 07:30 PM Eastern

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

XBiotech NASDAQ:XBIT

$1.93 -0.04 (-2.03%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$1.93 0.00 (0.00%)

As of 10/23/2026 07:30 PM Eastern

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XBIT, IMRX, SABS, and QTTB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XBIT, IMRX, SABS, and QTTB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XBIT, IMRX, SABS, and QTTB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT, IMRX, SABS, and QTTB Company Descriptions

Immuneering NASDAQ:IMRX

Q32 Bio NASDAQ:QTTB

SAB Biotherapeutics NASDAQ:SABS

XBiotech NASDAQ:XBIT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XBIT, IMRX, SABS, and QTTB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XBIT, IMRX, SABS, and QTTB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XBIT, IMRX, SABS, and QTTB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT, IMRX, SABS, and QTTB Company Descriptions

Immuneering NASDAQ:IMRX

Q32 Bio NASDAQ:QTTB

SAB Biotherapeutics NASDAQ:SABS

XBiotech NASDAQ:XBIT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools